Advertisement

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Welcome and Introduction to Vi3C

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Varsha Gandhi, PhD, on Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Oct
20
Today In Oncology
Mocertatug Rezetecan (Mo-Rez) Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
National Academy of Medicine Elects 100 New Members for 2026
Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera
ASH Issues New Recommendations for the Management of Myelofibrosis
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo